Healthcare Industry News: Gamida Cell
News Release - January 12, 2006
Gamida Cell Announces New Supporting Evidence That an Ex-Vivo Expanded Population of Human Bone Marrow Stem Cells May Help Treat Heart DiseaseData to Be Presented at The Second International Conference on Cell Therapy for Cardiovascular Diseases at the New York Academy of Medicine, January 19, 2006
JERUSALEM--(HSMN NewsFeed)--Jan. 12, 2006--Gamida Cell Ltd., developer of expanded stem cell therapeutics, announced today that its technology for the ex-vivo expansion of bone marrow-derived stem cells for the treatment of cardiovascular diseases will be presented at The Second International Conference on Cell Therapy for Cardiovascular Diseases at The New York Academy of Medicine, located at 1216 Fifth Avenue, in New York, New York. The presentation will include data collected in 2005, which supports previous evidence that an ex-vivo expanded population of human bone marrow stem cells may help patients who suffer from cardiac disease.
"We are proud to have been invited to present Gamida Cell's technology at this most important industry forum. The pre-clinical cardiac research has produced remarkable results in improving cardiac function. We hope that patients will also see benefits from this research in our soon to begin clinical trial," said Dr. Fuchs.
Gamida Cell reported in September 2004 findings that indicate that application of ex-vivo expanded bone marrow derived CD133+ cells improved cardiac function in a nude rat model with myocardial infarction.
Gamida Cell plans to begin a Phase I/II study with cardiac patients during the second half of 2006. The trial will investigate the effects of ex vivo expanded autologous (from the patient) bone marrow-derived CD133+ cells in patients with heart disease.
About Gamida Cell
Gamida Cell Ltd., (www.gamida-cell.com), is a leader in expanded hematopoietic (blood) stem cell therapeutics in clinical development for cancer, and cardiac diseases, as well as future regenerative cell-based medicines in preclinical development. The combined market potential of Gamida Cell's expanded stem cell products is estimated at $30 billion worldwide. Gamida Cell is currently pursuing partnerships and strategic alliances. Gamida Cell's President and CEO is Dr. Yael Margolin. Investors include Elscint (Europe-Israel), Biomedical Investments, Teva Pharmaceutical Industries, Denali Ventures, Auriga Ventures, Pamot and Comsor.
Source: Gamida Cell
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.